ThinkSabio

$LLY

$1206.82▲ +3.5% YTD

19 SEC 13D/G filings tracked · Last updated Oct 14, 2026

Filing History
News
LLY ▲ +3.5% - Eli Lilly and Company
CP $1206.82▲ +3.5%Oct 14, 2026 · ThinkSabio Blog

$LLY highs…

News
LLY ▼ -0.5% - Eli Lilly and Company
CP $1164.00▲ -0.5%Oct 9, 2026 · ThinkSabio Blog

$LLY ELI LILY: TALTZ AND ZEPBOUND TOGETHER SHOW BROADER BIOMARKER CHANGES VS. TALTZ ALONE || NEW PHASE 3B DATA ON LILLY'S TALTZ AND ZEPBOUND ADVANCE U…

News
LLY ▼ -0.5% - Eli Lilly and Company
CP $1164.00▲ -0.5%Oct 9, 2026 · ThinkSabio Blog

$LLY - New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic bio…

News
LLY ▼ -0.1% - Eli Lilly and Company
CP $1142.85▲ -0.1%Oct 5, 2026 · ThinkSabio Blog

$LLY - Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chroni…

News
LLY ▼ -0.4% - Eli Lilly and Company
CP $1147.23▲ -0.4%Oct 2, 2026 · ThinkSabio Blog

$LLY - Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certai…

News
LLY ▼ -2.0% - Eli Lilly and Company
CP $1162.55▲ -2.0%Sep 30, 2026 · ThinkSabio Blog

$LLY - Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its larges…

News
LLY ▲ +0.6% - Eli Lilly and Company
CP $1193.01▲ +0.6%Sep 30, 2026 · ThinkSabio Blog

$LLY - Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults…

News
LLY ▲ +0.0% - Eli Lilly and Company
CP $1186.00▲ +0.0%Sep 29, 2026 · ThinkSabio Blog

$LLY *LILLY'S RETATRUTIDE CUTS WEIGHT AVG 20.8% OVER 80 WKS IN PH. 3 *ELI LILLY - TO SUBMIT BIOLOGICS LICENSE APPLICATION FOR RETATRUTIDE IN Q1 2027…

News
LLY ▼ -0.2% - Eli Lilly and Company
CP $1183.77▲ -0.2%Sep 29, 2026 · ThinkSabio Blog

$LLY - Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with ob…

News
LLY ▼ -0.8% - Eli Lilly and Company
CP $1175.99▲ -0.8%Sep 29, 2026 · ThinkSabio Blog

$LLY tons of powerful news versus Novo on weight loss drugs. Being ignored - Cramer…

News
LLY ▲ +0.2% - Eli Lilly and Company
CP $1187.93▲ +0.2%Sep 29, 2026 · ThinkSabio Blog

$LLY Eli Lilly: Foundayo Shows Greater Weight Loss and A1C Reduction vs. Oral Semaglutide 25 mg in Indirect Comparison ? • At 52 weeks, Foundayo 17.2…

News
LLY ▲ +0.3% - Eli Lilly and Company
CP $1187.59▲ +0.3%Sep 29, 2026 · ThinkSabio Blog

$LLY - Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabe…

News
LLY ▲ +2.3% - Eli Lilly and Company
CP $1180.17▲ +2.3%Sep 24, 2026 · ThinkSabio Blog

$LLY highs…

News
LLY ▼ -0.4% - Eli Lilly and Company
CP $1148.57▲ -0.4%Sep 24, 2026 · ThinkSabio Blog

$LLY US FDA OKS LILLY'S ONSWIK…

News
LLY ▲ +1.2% - Eli Lilly and Company
CP $1165.50▲ +1.2%Sep 21, 2026 · ThinkSabio Blog

$LLY BREAKS GROUND ON $6.5B HOUSTON PLANT TO MAKE ORAL GLP-1 DRUG FOUNDaYO Eli Lilly has started construction on a roughly 1M-square-foot manufacturin…

News
LLY ▲ +1.2% - Eli Lilly and Company
CP $1165.50▲ +1.2%Sep 21, 2026 · ThinkSabio Blog

$LLY - Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020…

News
LLY ▲ +1.7% - Eli Lilly and Company
CP $1157.00▲ +1.7%Sep 15, 2026 · ThinkSabio Blog

$LLY - Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health…

News
LLY ▲ +1.1% - Eli Lilly and Company
CP $1172.94▲ +1.1%Sep 1, 2026 · ThinkSabio Blog

$LLY - Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference…

News
LLY ▲ +0.9% - Eli Lilly and Company
CP $1185.61▲ +0.9%Aug 28, 2026 · ThinkSabio Blog

$LLY - FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes…